IMC Microwave Industries News
8 articles
growth-positive
/CNW/ -- IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a leading medical cannabis company with operations in Israel and Germany, today announced...
IM Cannabis Corp., a leading medical cannabis company operating in Israel and Germany, has announced significant changes to its Board of Directors. Effective September 15, 2025, Shmulik Arbel and Brian Schinderle have resigned, and Asaf Yitzhaik and Eli Zamir have been appointed to fill their positions. Additionally, Oz Adler has been appointed as the new Chairman of the Board. The company is exploring new business activities to enhance long-term growth and shareholder value. IM Cannabis is committed to leveraging its transnational ecosystem and data-driven approach to strengthen its position in the medical cannabis markets of Israel and Germany.
Management Changes
growth-positive
/PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a leading medical cannabis company with operations in Israel and Germany, today...
IM Cannabis Corp., a leading medical cannabis company operating in Israel and Germany, announced significant changes to its Board of Directors. Effective September 15, 2025, Shmulik Arbel and Brian Schinderle resigned, with Asaf Yitzhaik and Eli Zamir appointed to fill their positions. Additionally, Oz Adler was appointed as the new Chairman of the Board. The company is exploring new business activities to enhance long-term growth and shareholder value. IM Cannabis focuses on providing premium cannabis products to medical patients in Israel and Germany, leveraging a data-driven approach and a global supply chain. The company aims to amplify its commercial and brand power while complying with strict regulatory environments.
Management Changes
growth-positive
/CNW/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ: IMCC), an international medical cannabis company, announced its financial results today for the...
IM Cannabis Corp. reported strong financial results for Q2 2025, despite facing external challenges such as the ongoing war in Israel and supply chain delays. The company experienced a 14% decrease in revenue compared to Q2 2024, primarily due to decreased revenue in Israel. However, it achieved a 306% increase in gross profit and a 371% increase in gross margin. The companys EBITDA improved significantly, turning a profit of $0.1 million from a loss of $2.3 million in the previous year. The management remains optimistic about recovering the revenue impact in the coming quarters and is focused on sustainable growth.
growth-positive
/PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ: IMCC), an international medical cannabis company, announced its financial results today for...
IM Cannabis Corp. reported strong financial results for Q2 2025, despite a 14% revenue decline compared to Q2 2024, attributed to external challenges such as the ongoing war in Israel and supply chain delays. The company achieved a 306% increase in gross profit and a 371% increase in gross margin, reflecting disciplined cost management and operational efficiency. The EBITDA turned positive with a profit of $0.1 million, compared to a loss of $2.3 million in the previous year. The company remains focused on sustainable growth and expects to recover the revenue impact in the coming quarters.
growth-positive
/CNW/ -- IM Cannabis Corp. (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany,...
IM Cannabis Corp., a leading medical cannabis company with operations in Israel and Germany, is set to report its operational and financial results for the second quarter of 2025 on August 12, 2025. The company focuses on sustainable and profitable growth in its key markets, leveraging a data-driven approach and a globally sourced product supply chain. IMC operates through subsidiaries in Israel, providing cannabis to medical patients and managing retail pharmacies, online platforms, and distribution centers. In Germany, it distributes cannabis to pharmacies through Adjupharm GmbH. The companys commitment to responsible growth and compliance aims to enhance its commercial and brand power globally.
growth-positive
/PRNewswire/ -- IM Cannabis Corp. (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and...
IM Cannabis Corp., a leading medical cannabis company with operations in Israel and Germany, is set to report its operational and financial results for the second quarter of 2025 on August 12, 2025. The company focuses on providing premium cannabis products to medical patients in two of the largest medical cannabis markets, Israel and Germany. IM Cannabis aims for sustainable and profitable growth by leveraging a transnational ecosystem powered by a data-driven approach and a globally sourced product supply chain. The company operates through subsidiaries in Israel and Adjupharm GmbH in Germany, distributing cannabis to pharmacies and medical patients.
growth-positive
/PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased...
IM Cannabis Corp., a leading medical cannabis company operating in Israel and Germany, has appointed Mr. Oz Adler to its board of directors. This appointment is part of a loan agreement with L.I.A. Pure Capital Ltd., which provided IM Cannabis with an initial loan of USD 1 million, with the potential for an additional USD 1 million. The company aims to raise at least USD 3 million through an underwritten offering. Mr. Adlers extensive experience in capital markets and pharmaceutical ventures is expected to support IM Cannabiss strategic growth and profitability. The company is focused on expanding its footprint in the medical cannabis markets of Israel and Germany.
Management ChangesInvestment
growth-positive
/CNW/ -- IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to...
IM Cannabis Corp. has appointed Mr. Oz Adler to its board of directors, effective July 6, 2025, as part of a loan agreement with L.I.A. Pure Capital Ltd. The company received a $1 million loan tranche, with a potential second tranche of the same amount by September 4, 2025. The loan is secured by a pledge over shares of IMC Holdings Ltd. and carries an 8% annual interest rate. IM Cannabis aims to raise $3 million within 60 days through an underwritten offering. Mr. Adlers appointment and financial expertise are expected to support the companys strategic growth in Israel and Germany.
Management ChangesInvestment
